49 results on '"VETTORI, Serena"'
Search Results
2. Fulminant Myocarditis Unmasking Adult-Onset Still’s Disease and Desmoplakin Truncation
3. Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort
4. Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects
5. A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate COVID-19
6. Idiopathic pulmonary fibrosis and systemic sclerosis-interstitial lung disease: features at admission to a tertiary pulmonology unit
7. Translational engagement of lysophosphatidic acid receptor 1 in skin fibrosis: from dermal fibroblasts of patients with scleroderma to tight skin 1 mouse
8. T-Cell Proapoptotic and Antifibrotic Activity Against Autologous Skin Fibroblasts in vitro Is Associated With IL-17A Axis Upregulation in Systemic Sclerosis
9. Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database
10. Prediction of organ involvement and survival in systemic sclerosis patients in the first 5 years from diagnosis
11. Performance of a new quantitative computed tomography index for interstitial lung disease assessment in systemic sclerosis
12. OP0063 SAFETY OF MYCOPHENOLATE MOFETIL TREATMENT IN SYSTEMIC SCLEROSIS IN REAL LIFE: REPORT FROM A SINGLE CENTER LARGE COHORT OBSERVATIONAL STUDY
13. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study
14. Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis
15. Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association
16. Hemodynamic changes after acute fluid loading in patients with systemic sclerosis without pulmonary hypertension
17. Esophageal high-resolution impedance manometry alterations in asymptomatic patients with systemic sclerosis: prevalence, associations with disease features, and prognostic value
18. Fluid challenge test and pulmonary haemodynamics in patients with systemic sclerosis
19. International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?
20. Mapping and predicting mortality from systemic sclerosis
21. The cumulative number of micro-haemorrhages and micro-thromboses in nailfold videocapillaroscopy is a good indicator of disease activity in systemic sclerosis: a validation study of the NEMO score
22. Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis
23. Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group
24. Longitudinal analysis of quality of life in patients with undifferentiated connective tissue diseases
25. N-terminal pro-brain natriuretic peptide is a strong predictor of mortality in systemic sclerosis
26. CXCL4 in undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (previously referred to as very early SSc)
27. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index
28. Serum CXCL4 increase in primary Sjögren’s syndrome characterizes patients with microvascular involvement and reduced salivary gland infiltration and lymph node involvement
29. Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease
30. Outcome of a glucocorticoid discontinuation regimen in patients with inactive systemic sclerosis
31. Right atrial morphology and function in patients with systemic sclerosis compared to healthy controls: a two-dimensional strain study
32. IL-22 capacitates dermal fibroblast responses to TNF in scleroderma
33. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database
34. Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): Efficacy of maintenance immunosuppression in responders and non-responders
35. Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression
36. Early Systemic Sclerosis: Analysis of the Disease Course in Patients With Marker Autoantibody and/or Capillaroscopic Positivity
37. High IL-17E and Low IL-17C Dermal Expression Identifies a Fibrosis-Specific Motif Common to Morphea and Systemic Sclerosis
38. Early Systemic Sclerosis: Serum Profiling of Factors Involved in Endothelial, T-cell, and Fibroblast Interplay is Marked by Elevated Interleukin-33 Levels
39. The Concept of Early Systemic Sclerosis Following 2013 ACR\EULAR Criteria for the Classification of Systemic Sclerosis
40. Tissue Doppler imaging in systemic sclerosis: A 3-year longitudinal study
41. A3.19 mIR-193B induces UPA in SSC and contributes to the proliferative vasculopathy via uPAR independent pathways
42. Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis
43. A7.3 Association of Circulating miR-223 and miR-16 with Disease Activity in Patients with Early Rheumatoid Arthritis
44. Early systemic sclerosis: marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markers
45. Quality of life as measured by the short-form 36 (SF-36) questionnaire in patients with early systemic sclerosis and undifferentiated connective tissue disease
46. Role of MicroRNAs in Fibrosis
47. MiRs in RA: possible biomarkers and therapeutic targets
48. Early systemic sclerosis: short-term disease evolution and factors predicting the development of new manifestations of organ involvement
49. Non-Hodgkin’s lymphoma in systemic sclerosis: case and literature review
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.